Stockscreener 앱 받기
5.00
4.40%
-0.23
시간 외 거래:
4.98
-0.02
-0.40%
Atara Biotherapeutics Inc 주식(ATRA)의 최신 뉴스
What are analysts price targets for Atara Biotherapeutics Inc2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
[S-3] Atara Biotherapeutics, Inc. Shelf Registration Statement | ATRA SEC FilingForm S-3 - Stock Titan
Market Recap: Will Atara Biotherapeutics Inc benefit from AI trendsEarnings Trend Report & Weekly Momentum Stock Picks - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application - Investing.com Nigeria
Atara Biotherapeutics, Inc. 2025 Annual Report: Strategic Alternatives, Business Overview, and Risk Factors - Minichart
Atara Biotherapeutics: Q4 Loss & Annual Profit 2025 Financial ResultsNews and Statistics - IndexBox
Atara Biotherapeutics: Q4 Earnings Snapshot - KTVB
Atara Biotherapeutics (NASDAQ: ATRA) registers $11.1M ATM offering via TD Cowen - Stock Titan
Atara Biotherapeutics (ATRA) bets on tab-cel as layoffs, FDA pushback mount - Stock Titan
Atara (NASDAQ: ATRA) turns 2025 profit and targets cash runway into 2026 - Stock Titan
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - The Joplin Globe
Atara Biotherapeutics: Fourth Quarter Earnings Overview - Bitget
Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” - The Cancer Letter
Weekly Trades: Will Atara Biotherapeutics Inc benefit from AI trendsQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel - marketscreener.com
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus
Atara Plans FDA Type A Meeting on EBVALLO - TipRanks
Atara Biotherapeutics schedules FDA Type A meeting on EBVALLO BLA complete response - TradingView
FDA to hold Type A meeting on Atara Biotherapeutics (ATRA) EBVALLO tab-cel BLA - Stock Titan
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire
Atara (ATRA) CEO granted 81,100 RSUs, now holds 143,078 shares - Stock Titan
Atara Biotherapeutics (ATRA) awards 20,300 RSUs to Chief Accounting Officer - Stock Titan
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus - TechStock²
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aug Closing: Can Atara Biotherapeutics Inc sustain earnings growth2026 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Chart Watch: Is Atara Biotherapeutics Inc being accumulated by smart moneyJobs Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Why Atara Biotherapeutics Inc. stock is popular among millennials2025 Trading Recap & Verified Entry Point Signals - Naître et grandir
Aug Momentum: Is Atara Biotherapeutics Inc forming a breakout patternJuly 2025 Catalysts & Short-Term Swing Trade Alerts - baoquankhu1.vn
Profit Review: Will Atara Biotherapeutics Inc benefit from green energy policiesEarnings Recap Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection - Stocktwits
Atara Biotherapeutics (ATRA) CEO sells 2,996 shares to cover RSU taxes - Stock Titan
Atara Biotherapeutics provides regulatory update on tabelecleucel - marketscreener.com
Atara, Pierre Fabre seek FDA meeting on EBVALLO - TipRanks
Atara Biotherapeutics (ATRA) and Partner Seek FDA Meeting for Ta - GuruFocus
Atara Biotherapeutics partner seeks Type A FDA meeting on tabelecleucel following CRL - TradingView
Atara Biotherapeutics (ATRA) requests FDA Type A meeting on EBVALLO™ - Stock Titan
Atara Biotherapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Insider sale: ATRA (NASDAQ: ATRA) 7,788 RSU shares settled 03/01/2026 - Stock Titan
ATRA (NASDAQ) insider resale notice: 4,759 RSU shares reported - Stock Titan
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ATRA Should I Buy - Intellectia AI
Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection - GuruFocus
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Market Overview: Can Atara Biotherapeutics Inc stock double in the next yearStock Surge & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Atara extends $9M milestone payment deadline to 2028 By Investing.com - Investing.com Australia
Atara Biotherapeutics Provides a Business Update - BioSpace
Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement - GuruFocus
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant - TipRanks
Atara Biotherapeutics Defers $9 Million Milestone Payment to 2028, Issues 400,000-Share Warrant to HCR - TradingView
Atara extends $9M milestone payment deadline to 2028 - Investing.com
Atara (NASDAQ: ATRA) extends $9M HCRx payment and grants 400,000-share warrant - Stock Titan
0.69%
자본화:
|
볼륨(24시간):